title: [Clinical study of endocrine therapy in stage B and C prostate cancer].
abstract: To evaluate the usefulness of endocrine therapy for stage B and C prostate cancer, we carried out a retrospective study on overall survival rate, cause-specific survival, PSA recurrence-free rate, and their predictive factors in 118 patients with stage B prostate cancer, 61 with stage C prostate cancer who underwent endocrine therapy at our department between 1985 and 2001. The cause-specific survival rate and PSA recurrence-free rate of stage B patients who underwent endocrine therapy were well, and they will take a good clinical course. Thus, in this stage of prostate cancer, aged patients and patients with complications may be good candidates for endocrine therapy. The cause-specific survival rate and PSA recurrence-free rate in the stage C patients who underwent endocrine therapy were significantly low. In stage C patients, endocrine therapy should be combined early with other methods such as radiotherapy. In the stage B patients who underwent endocrine therapy, PSA and Gleason score appeared to be associated with the cause-specific survival rate and PSA recurrence-free rate.
authors.affiliation: Department of Urology, Tatebayashi Kousei Hospital.
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Uei
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okazaki
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Nakamura
authors.forename: Nobuo
authors.initials: N
authors.lastname: Katou
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Yamanaka
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal